We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks t... Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology. Show more
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on January 13, 2025, the Compensation Committee of Acadiaโs Board of Directors (the โCommitteeโ) granted inducement awards...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced multiple business updates and progress on the Company's CNS and rare disease drug candidates, which will be discussed today during a...
Acadia Pharmaceuticals Set to Join S&P SmallCap 600 PR Newswire NEW YORK, Dec. 30, 2024 NEW YORK, Dec. 30, 2024 /PRNewswire/ -- Acadia Pharmaceuticals Inc. (NASD: ACAD) will replace...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Catherine Owen Adams, Chief Executive...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on December 4, 2024, the Compensation Committee of Acadiaโs Board of Directors (the โCommitteeโ) granted inducement awards...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million before fees and expenses. As...
โ Seasoned commercial executive with more than 25 years pharmaceutical and biotech experience Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Thomas Andrew Garner has been...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.34 | 1.97330237957 | 17.23 | 18.225 | 16.61 | 2093135 | 17.36547463 | CS |
4 | 1.06 | 6.42035130224 | 16.51 | 19.39 | 16.49 | 4730023 | 17.96026616 | CS |
12 | 3.05 | 21.0055096419 | 14.52 | 19.39 | 14.31 | 2473045 | 17.42793818 | CS |
26 | -0.97 | -5.23193096009 | 18.54 | 19.44 | 14.15 | 1989789 | 16.93512096 | CS |
52 | -11.05 | -38.6093640811 | 28.62 | 29.29 | 14.15 | 1876190 | 18.06459471 | CS |
156 | -5.21 | -22.8709394205 | 22.78 | 33.99 | 12.24 | 1752369 | 19.9486561 | CS |
260 | -27.36 | -60.894725128 | 44.93 | 58.72 | 12.24 | 1661560 | 24.85447261 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions